We sought to determine whether and how STAT3/MCL1 signaling axis is involved in sorafenib-induced ferroptosis and to identify potential biomarkers for selecting NSCLC patients who may benefit from treatment with ferroptosis-inducing agents. Here, MCL1 is linked to non-small cell lung carcinoma.